Novartis has announced plans to construct a new US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida.

MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of ...

After signing a drug pricing deal with the White House, J&J will now offer some of its branded medicines at discounted rates ...

Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector ...

GlobalData’s detailed strategic reports on the MFN executive order and on the GENEROUS model examined how some of the known ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Santhera Pharmaceuticals has entered into an exclusive licensing agreement with Nxera Pharma for Agamree to treat DMD in ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Octapharma has received approval from the US FDA for a new 2-g formulation of Fibryga for use in patients with AFD.

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...